Efficacy of intermittent etidronate therapy for corticosteroid-induced osteoporosis in patients with diffuse connective tissue disease

Kurume Medical Journal

Volumn 47, Issue 3, 2000, Pages 219-224

  Jinnouchi, Yoshikazu ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Bone metabolism marker; Bone salt minerals assay level; Combination therapy with active vitamin D3 and etidronate; Corticosteroid induced osteoporosis; Cyclic intermittent etidronate; Diffuse connective tissue disease; New spinal compression fracture ratio

Indexed keywords

ALKALINE PHOSPHATASE; BIOCHEMICAL MARKER; COLECALCIFEROL; CORTICOSTEROID; DEOXYPYRIDINOLINE; ETIDRONIC ACID;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE METABOLISM; CLINICAL ARTICLE; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; FEMALE; FRACTURE; HUMAN; MALE; OSTEOPOROSIS;

EID: 0033777710     PISSN: 00235679     EISSN: None     Source Type: Journal    
DOI: 10.2739/kurumemedj.47.219     Document Type: Article

References (23)

1. Adachi JD, Bensen WG, Bianchi F, Cividino A, Pillersdorf S et al. Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis: a 3 year followup. J Rheumatol 1996; 23:995-1000.
2. Hall GM, Daniels M, Doyle DV, and Spector TD. Effect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treated with and without steroids. Arthritis Rheum 1994; 37:1499-1505.
3. Luengo M, Pons F, Martinez de Osaba MJ, and Picado C. Prevention of further bone mass loss by nasal calcitonin in patients on long term glucocorticoid therapy for asthma: a two year follow up study. Thorax 1994; 49:1099-1102.
4. Orimo H, Sugioka Y, Fukunaga M, Mutoh Y, Hotokebuchi T et al. Diagnosis criteria of primary osteoporosis (revised in 1996). Osteoporosis Japan 1996; 4: 643-653. (in Japanese)
5. Fujita T, Orimo H, and Inoue T. A study of dose establishment with EHDP for osteoporosis. Kiso To Rinshou (Basic And Clinical Study) 1994; 28:447-486. (in Japanese)
6. Fukunaga H. Osteoporosis And Bone Minerals Assay - Bone Minerals Assay by DXA, ed. Fukunaga H, Medical Review Co., Ltd., Tokyo, 1995. (in Japanese)
7. Kanis JA. Osteoporosis and osteopenia. J Bone Miner Res 1990; 5:209-211.
8. Gallagher JC, Jerpbak CM, Jee WS, Johnson KA, DeLuca HF et al. 1,25-Dihydroxyvitamin D3:Short-and long-term effects on bone and calcium metabolism in patients with postmenopausal osteoporosis. Proc Natl Acad Sci USA 1982; 79:3325-3329.
9. Tilyard MW, Spears GF, Thomson J, and Dovey S. Treatment of postmenopausal osteoporosis with calcitriol or calcium. N Engl J Med 1992; 326:357-362.
10. Reid IR, and Ibbertson HK. Calcium supplements in the prevention of steroid-induced osteoporosis. Am J Clin Nutr 1986; 44:287-290.
11. Hochberg MC, Prashker MJ, Greenwold M, Hannan MT, Lane NE et al. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. American College of Rheumatology Task Force on Osteoporosis Guidelines. Arthritis Rheum 1996; 39: 1791-1801.
12. Eastell R, Reid DM, Compston J, Cooper C, Fogelman I et al. A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update. J Intern Med 1998; 244:271-292.
13. Adachi JD, Bensen WG, Brown J, Hanley D, Hodsman A et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 1997; 337:382-387.
14. Roux C, Oriente P, Laan R, Hughes RA, Ittner J et al. Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss. Ciblos Study Group. J Clin Endocrinol Metab 1998; 83:1128-1133.
15. Adachi JD, Cranney A, Goldsmith CH, Bensen WG, Bianchi F et al. Intermittent cyclic therapy with etidronate in the prevention of corticosteroid-induced bone loss. Can J Rheumatol 1994; 21:1922-1926.
16. Struys A, Snelder AA, and Mulder H. Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis. Am J Med 1995; 99:235-242.
17. Hughes DE, MacDonald BR, Russell RG, and Gowen M. Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow. J Clin Invest 1989; 83:1930-1935.
18. Murakami H, Takahashi N, Sasaki T, Udagawa N, Tanaka S et al. A possible mechanism of the specific action of bisphosphonates on osteoclasts: tiludronate preferentially affects polarized osteoclasts having ruffled borders. Bone 1995; 17:137-144.
19. Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 1995; 10:1478-1487.
20. Miller PD, Watts NB, Licata AA, Harris ST, Genant HK et al. Cyclical etidronate in the treatment of postmenopausal osteoporosis: efficacy and safety after seven years of treatment. Am J Med 1997; 103:468-476.
21. Garnero P, and Delmas PD. New developments in biochemical markers for osteoporosis. Calcif Tissue Int 1996; 59:2-9.
22. Ross PD, Davis JW, Epstein RS, and Wasnich RD. Preexisting fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med 1991; 114:919-923.
23. Nakatsuka K, and Nishizawa Y. Drug therapy for osteoporosis. (1) Selection of the drugs and combination therapy. Rinshou Kagaku (Clinical Science) 1998; 34: 1351-1358. (in Japanese)